AstraZeneca enters blood cancer drug into race for Covid-19 treatments
The company said it had initiated a trial of Calquence for treating cytokine storm associated with the disease. The drug is a BTK inhibitor approved for certain forms of leukemia and lymphoma, and the drugmaker said inhibiting BTK may have an effect on overactive immune responses.